Loading...
Loading...
PSTV| Name | Value |
|---|---|
| Revenues | 1,279.0K |
| Cost of Revenue | 202.0K |
| Gross Profit | 1,077.0K |
| Operating Expense | 4,774.0K |
| Operating I/L | -3,697.0K |
| Other Income/Expense | 757.0K |
| Interest Income | 67.0K |
| Pretax | -2,940.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -2,940.0K |
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company specializing in the development, manufacturing, and commercialization of treatments for cancer and other diseases. Their lead drug candidate, Rhenium-186 NanoLiposome, is a patented radiotherapy designed to target central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also holds a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment, further expanding their product portfolio in the oncology space.
